Abstract
Enterobacter is a globally important pathogen. Here we clarify its taxonomy and review recent developments in its resistance to carbapenem and colistin, illustrating that Enterobacter has a large arsenal of mechanisms to grow under antimicrobial pressure. Further studies are required to decipher colistin heteroresistance and understand why certain Enterobacter lineages have emerged clinically.
| Original language | English |
|---|---|
| Pages (from-to) | 473-476 |
| Number of pages | 4 |
| Journal | Trends in Microbiology |
| Volume | 29 |
| Issue number | 6 |
| Early online date | 8 Jan 2021 |
| DOIs | |
| Publication status | Published - Jun 2021 |
Bibliographical note
Funding Information:Relevant research works of the author are supported by grants from the National Natural Science Foundation of China (project no. 81772233 , 81661130159 and 81861138055 ), West China Hospital of Sichuan University (1.3.5 project for disciplines of excellence, project no. ZYYC08006 ; and grant no. 312190022 ), the Newton Advanced Fellowship, Royal Society, UK ( NA150363 ), and the Medical Research Council ( MR/S013660/1 ).
Keywords
- Enterobacter
- antimicrobial resistance
- carbapenem resistance
- colistin resistance
- high-risk lineages
- taxonomy
ASJC Scopus subject areas
- Microbiology
- Microbiology (medical)
- Infectious Diseases
- Virology
